Literature DB >> 9108183

IL-1beta and IL-6 in community-acquired pneumonia: bacteremic pneumococcal pneumonia versus Mycoplasma pneumoniae pneumonia.

D Lieberman1, S Livnat, F Schlaeffer, A Porath, S Horowitz, R Levy.   

Abstract

Interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) levels in 20 patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia (CAP) were compared with these cytokine levels in 20 patients with Mycoplasma pneumoniae CAP. All 40 patients survived hospitalization and underwent a follow-up examination one month later. Serum IL-1beta and IL-6 levels were determined by the enzyme immunoassay (EIA) method using commercial kits. In the acute phase of CAP, IL-6 levels were significantly higher in the S. pneumoniae group (p = 0.014), while IL-1beta levels were higher in the M. pneumoniae group (p = 0.046). In the convalescence phase, the two cytokines were detected in a considerable number of patients in both groups. In this phase, only the level of IL-1beta was significantly higher in the M. pneumoniae group than in the S. pneumoniae group (p = 0.03). We conclude that the levels of IL-1beta and IL-6 are different between patients with S. pneumoniae-CAP and M. pneumoniae-CAP during the acute phase. In the convalescence phase, cytokine levels remain high in some of the CAP patients, but a significant difference between the groups exists only for IL-1beta. Further studies are required.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108183     DOI: 10.1007/bf02113582

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  19 in total

Review 1.  Community-acquired pneumonia.

Authors:  J G Bartlett; L M Mundy
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

2.  Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients.

Authors:  D Lieberman; F Schlaeffer; I Boldur; D Lieberman; S Horowitz; M G Friedman; M Leiononen; O Horovitz; E Manor; A Porath
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

3.  Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor.

Authors:  B C Sheppard; D L Fraker; J A Norton
Journal:  Surgery       Date:  1989-08       Impact factor: 3.982

4.  Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study.

Authors:  P Marik; P Kraus; J Sribante; I Havlik; J Lipman; D W Johnson
Journal:  Chest       Date:  1993-08       Impact factor: 9.410

5.  APACHE-acute physiology and chronic health evaluation: a physiologically based classification system.

Authors:  W A Knaus; J E Zimmerman; D P Wagner; E A Draper; D E Lawrence
Journal:  Crit Care Med       Date:  1981-08       Impact factor: 7.598

Review 6.  Acute inflammation in gram-negative infection: endotoxin, interleukin 1, tumor necrosis factor, and neutrophils.

Authors:  H Z Movat; M I Cybulsky; I G Colditz; M K Chan; C A Dinarello
Journal:  Fed Proc       Date:  1987-01

7.  Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality.

Authors:  M R Pinsky; J L Vincent; J Deviere; M Alegre; R J Kahn; E Dupont
Journal:  Chest       Date:  1993-02       Impact factor: 9.410

8.  High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group.

Authors:  T Calandra; J Gerain; D Heumann; J D Baumgartner; M P Glauser
Journal:  Am J Med       Date:  1991-07       Impact factor: 4.965

9.  Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

Authors:  B Beutler; N Krochin; I W Milsark; C Luedke; A Cerami
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

10.  Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans.

Authors:  P Damas; A Reuter; P Gysen; J Demonty; M Lamy; P Franchimont
Journal:  Crit Care Med       Date:  1989-10       Impact factor: 7.598

View more
  9 in total

1.  Reactive oxygen species mediate Jak2/Stat3 activation and IL-8 expression in pulmonary epithelial cells stimulated with lipid-associated membrane proteins from Mycoplasma pneumoniae.

Authors:  Sang Yong Choi; Joo Weon Lim; Takashi Shimizu; Koichi Kuwano; Jung Mogg Kim; Hyeyoung Kim
Journal:  Inflamm Res       Date:  2012-01-24       Impact factor: 4.575

2.  Serum cytokine responses in primary pneumonic plague patients.

Authors:  Xiaoyi Wang; Zuyun Wang; Zhaobiao Guo; Baiqing Wei; Fuzhang Tian; Shouhong Yu; Haoran Wang; Hu Wang; Ruifu Yang
Journal:  Clin Vaccine Immunol       Date:  2010-11-24

Review 3.  Role of cytokines in pulmonary antimicrobial host defense.

Authors:  B Mehrad; T J Standiford
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 4.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

5.  Mycoplasma pneumoniae-derived lipopeptides induce acute inflammatory responses in the lungs of mice.

Authors:  Takashi Shimizu; Yutaka Kida; Koichi Kuwano
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

6.  Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.

Authors:  Ana María Ríos; Asunción Mejías; Susana Chávez-Bueno; Mónica Fonseca-Aten; Kathy Katz; Jeanine Hatfield; Ana María Gómez; Hasan S Jafri; George H McCracken; Octavio Ramilo; Robert Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 7.  Molecular biology and pathogenicity of mycoplasmas.

Authors:  S Razin; D Yogev; Y Naot
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

8.  Regulation of proinflammatory cytokines in human lung epithelial cells infected with Mycoplasma pneumoniae.

Authors:  Jun Yang; W Craig Hooper; Donald J Phillips; Deborah F Talkington
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

9.  Vaccination with Mycoplasma pneumoniae membrane lipoproteins induces IL-17A driven neutrophilia that mediates Vaccine-Enhanced Disease.

Authors:  Arlind B Mara; Tyler D Gavitt; Edan R Tulman; Jeremy M Miller; Wu He; Emily M Reinhardt; R Grace Ozyck; Meagan L Goodridge; Lawrence K Silbart; Steven M Szczepanek; Steven J Geary
Journal:  NPJ Vaccines       Date:  2022-07-29       Impact factor: 9.399

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.